IL17A and inflammatory bowel disease: A recent meta-analysis by Truong et al. suggests a slightly increased incidence of new-onset IBD in RCTs with patients receiving IL-17 inhibitors.11 The calculated odds ratio (OR) of IBD in the treated population was two or three times higher than the placebo or the active comparator (mainly TNF-α inhibitor), respectively.